Cardiomyopathy Clinical Trial
Official title:
Midterm Clinical Outcomes Related to Cardiac Resynchronization Therapy Deactivation of Super Responders
Verified date | September 2014 |
Source | Yuksek Ihtisas Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine clinical outcomes related to deactivation of Cardiac Resynchronization Therapy device in subjects with super response.
Status | Completed |
Enrollment | 19 |
Est. completion date | June 2014 |
Est. primary completion date | June 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility |
Inclusion Criteria: - super response to Cardiac Resynchronization Therapy - near normal Left ventricular ejection fraction - >99% pacing Exclusion Criteria: - <99% pacing - atrial fibrillation - ischemic cardiomyopathy |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Yuksek Ihtisas Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical/Echocardiographic outcome | Clinical/Echocardiographic outcome including New York Heart Association class, 6-min walk test, Left ventricular ejection fraction, Left ventricular end- diastolic diameter, Left ventricular end-systolic volume, and Left ventricular end-systolic diameter. | 12 months | |
Secondary | Mortality | Number of participants experiencing mortality | 12 months | |
Secondary | Heart failure hospitalization | Number of participants experiencing heart failure hospitalization | 12 months | |
Secondary | Cardiac Resynchronization Therapy Device intervention | Heart failure hospitalization Cardiac Resynchronization Therapy Device intervention for detected episodes. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 | |
Completed |
NCT02892448 -
Cardiac MRI for Metal on Metal Hip Resurfacing
|
N/A | |
Active, not recruiting |
NCT02537782 -
Myocardial Work and Metabolism in CRT
|
N/A | |
Completed |
NCT02525185 -
Contractile Reserve in Dyssynchrony: A Novel Principle to Identify Candidates for Cardiac Resynchronization Therapy
|
||
Terminated |
NCT01705509 -
The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC)
|
N/A | |
Completed |
NCT00999947 -
Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy
|
N/A | |
Completed |
NCT00626028 -
Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing
|
Phase 3 | |
Recruiting |
NCT00138931 -
Genetics of Cardiovascular and Neuromuscular Disease
|
||
Withdrawn |
NCT02838355 -
Employing End Tidal Capnography in Continuous Flow Ventricular Assist Device Patients
|
N/A | |
Completed |
NCT01085955 -
Investigation in Pregnancy Associate Cardiomyopathy
|
N/A | |
Withdrawn |
NCT00428103 -
Effects of Mitral Valve Repair With the Geoform Ring on Cardiomyopathy
|
N/A | |
Recruiting |
NCT00273637 -
Registry and Survey of Women With Pregnancy Related Cardiomyopathy
|
N/A | |
Completed |
NCT00810550 -
Carotid Ultrasound in the Evaluation of Heart Failure
|
N/A | |
Completed |
NCT04603521 -
Patients' Long-Term Survival of Obstructive Hypertrophic Cardiomyopathy (HCM)
|
||
Enrolling by invitation |
NCT03057561 -
Efficacy of Dotarem® (Gd-DOTA) Versus Gadovist® (Gd-DO3A-butrol) for Late Gadolinium Enhancement Cardiac Magnetic Resonance
|
N/A | |
Completed |
NCT00027170 -
Technical Development of Cardiovascular Magnetic Resonance Imaging
|
||
Not yet recruiting |
NCT02917395 -
Evaluate the Efficacy of Disopyramide Therapy in Hypertrophic Obstructive Cardiomyopathy Patients
|
N/A | |
Completed |
NCT02164721 -
Multicenter Automatic Defibrillator Implantation Trial - Chemotherapy-Induced Cardiomyopathy
|
N/A | |
Completed |
NCT02331264 -
Cardiac Assessment of Patients With Hip Implants
|
N/A | |
Completed |
NCT02270840 -
Budapest Upgrade CRT Study (Version 009-4.1)
|
N/A |